BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 9787169)

  • 1. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC; Linn YC; Hope EG; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
    Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE
    Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
    Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
    Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment of chronic myeloid leukemia in SCID mice.
    Hoyle CF; Negrin RS
    Hematol Oncol; 1998 Sep; 16(3):87-100. PubMed ID: 10235067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
    Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
    Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
    Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.
    Kornacker M; Moldenhauer G; Herbst M; Weilguni E; Tita-Nwa F; Harter C; Hensel M; Ho AD
    Int J Cancer; 2006 Sep; 119(6):1377-82. PubMed ID: 16642465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
    Baker J; Verneris MR; Ito M; Shizuru JA; Negrin RS
    Blood; 2001 May; 97(10):2923-31. PubMed ID: 11342413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.
    Mehta BA; Schmidt-Wolf IG; Weissman IL; Negrin RS
    Blood; 1995 Nov; 86(9):3493-9. PubMed ID: 7579455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
    World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.